Neuromuscular Therapeutics
Dr. Katzberg has expertise in observational as well as interventional clinical studies and trials with a special focus on immunotherapy for neuromuscular conditions such as myasthenia gravis (MG), and immune neuropathies (CIDP, MMN, GBS). He has served as coordinating investigator, site PI and on the steering committee for multi-centre studies and PI on investigator initiated trials as well as member and chair of mult-centre data safety monitoring boards (DSMB). He is a consultant to biotechnology companies during drug discovery and the development of novel technologies for the treatment of neuromuscular diseases.
Dr. Katzberg has been a member and consultant for multiple Canadian and International organizations including the Inflammatory Neuropathy Consortium branch of the Peripheral Nerve Society, International GBS Outcome Study (IGOS), Peripheral Neuropathy Outcome Measures Standardization Study (PERINOMS), Canadian Vaccine Injury Support Program (VISP), Canadian Drug and Therapeutics Commission (CADTH), National Advisory Centre for Immunotherapy (NACI), and Canadian Blood Services. Collection of clinical data and sharing expertise on immune therapies with stakeholders aims to improve the health of patients with neuromuscular disease.
